Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MG-5-3525
- Development stage
- Unknown
- Lead developer
- Metagone Biotech
- Modality
- Small Molecules
01
Overview
MG-5-3525 is a small molecule inhibitor of Mitogen-activated protein kinase 3 (MAPK3), also known as ERK1, currently in Phase 2 development by Metagone Biotech. It is being investigated for the treatment of chronic respiratory diseases, specifically bronchiectasis and chronic obstructive pulmonary disease (COPD). MAPK3 is a key mediator in the extracellular signal-regulated kinase (ERK) signaling pathway, which is involved in regulating inflammatory responses and cellular proliferation in the airways. By inhibiting MAPK3, MG-5-3525 aims to reduce the chronic inflammation and tissue remodeling associated with these pulmonary conditions.
02
Targets
MAPK3 (Mitogen-activated protein kinase 1)
Beyond the preview
Go deeper on MG-5-3525.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MG-5-3525.